Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation
Journal of Thrombosis and Haemostasis2020Vol. 18(7), pp. 1672–1685
Citations Over TimeTop 10% of 2020 papers
Guy Young, Anthonie W.A. Lensing, Paul Monagle, Christoph Male, Kirstin Thelen, Stefan Willmann, Joseph S. Palumbo, Riten Kumar, Ildar Nurmeev, Kerry Hege, Fanny Bajolle, Philip Connor, Hélène L. Hooimeijer, Marcela Torres, Anthony K.C. Chan, Gili Kenet, Susanne Holzhauer, Amparo Santamaría, Pascal Amédro, Jan Beyer‐Westendorf, Ida Martinelli, M. Patricia Massicotte, William T. Smith, Scott D. Berkowitz, Stephan Schmidt, Victoria Price, Martin H. Prins, Dagmar Kubitza
Related Papers
- → Assays for Measuring Rivaroxaban: Their Suitability and Limitations(2010)157 cited
- → Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation(2012)48 cited
- → Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?(2016)17 cited
- → Rivaroxaban for Thromboprophylaxis in Patients with Antiphospholipid Syndrome(2017)1 cited
- → Developing Deep Venous Thrombosis while on Rivaroxaban: A Review of Rivaroxaban(2020)1 cited